Emma Reeve
CIK 1680329 · Chief Financial Officer · last filed 2026-01-06
Emma Reeve is a Chief Financial Officer who has filed 45 SEC Form 4 insider transactions across 6 companies since 2016. The most recent filing, for PTCT, was dated Jan 6, 2026. Across all open-market trades the lifetime net is −$10.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $801.4K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$801.4K
6
45
-$10.27M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTCT | Director | 10,666 | $75.14 | $801.4K | -$6.12M | 18 | 2026-01-06 |
| WHWK | Director | — | $4.16 | — | $0 | 1 | 2025-06-16 |
| Whitehawk Therapeutics, Inc. (AADI) Delisted | Director | — | $2.05 | — | $0 | 4 | 2024-06-14 |
| EDIT | Director | — | $2.50 | — | $0 | 4 | 2024-06-03 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Chief Financial Officer | 6,260 | $33.99 | $212.8K | -$4.16M | 16 | 2021-02-23 |
| PAREXEL INTERNATIONAL CORP (PRXL) Delisted | Corp. VP & Interim CFO | 8,468 | — | — | $0 | 1 | 2016-12-09 |
Recent Filings
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-06 | PTCT | Mixed | +4,000 | -$21.6K | EDGAR |
| 2025-12-05 | PTCT | Mixed | — | -$23.5K | EDGAR |
| 2025-11-25 | PTCT | Mixed | — | -$283.4K | EDGAR |
| 2025-11-14 | PTCT | Mixed | — | -$205.0K | EDGAR |
| 2025-10-31 | PTCT | Mixed | −3,666 | -$631.6K | EDGAR |
| 2025-10-07 | PTCT | Mixed | — | -$772.7K | EDGAR |
| 2025-09-16 | PTCT | Mixed | −4,868 | -$649.4K | EDGAR |
| 2025-06-16 | WHWK | Grant (A) | — | $0 | EDGAR |
| 2025-01-07 | PTCT | Grant (A) | +4,000 | $0 | EDGAR |
| 2024-06-14 | Whitehawk Therapeutics, Inc. (AADI) Delisted | Grant (A) | — | $0 | EDGAR |